The role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines

Clinical Biochemistry

Volumn 29, Issue 2, 1996, Pages 149-155

  Rifai, Nader ^a   Chao, Fei Fei ^b   Pham, Quynhchi ^b   Thiessen, Jake ^c   Soldin, Steven J ^b,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cyclosporine; lipoproteins; tacrolimus

Indexed keywords

CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; TACROLIMUS; TRITIUM; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; HUMAN CELL; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL LINE; PH; PRIORITY JOURNAL; TEMPERATURE; THIN LAYER CHROMATOGRAPHY;

EID: 0029868042     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(96)00001-X     Document Type: Article

References (28)

1. Andrus L, Lafferty KJ. Inhibition of T-cell activity by cyclosporin A. Scand J Immunol 1981; 45: 371-375.
2. Kino T, Hatanaka H, Miyata S et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 1987; 40: 1256-1265.
3. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991; 13: 464-477.
4. Atkinson K, Britton K, Biggs J. Distribution and concentration of cyclosporin in human blood. J Clin Pathol 1984; 37: 1167-1171.
5. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: Therapeutic monitoring of Tacrolimus (Tacrolimus). Ther Drug Monitor. In press.
6. Niederberger W, Lemaire M, Maurer G, Nussbaumer K, Wagner O. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983; 15 (Suppl 1): 2419-2421.
7. Venkataramanan R, Jain A, Cadoff E et al. Pharmacokinetics of FK 506: Preclinical and clinical studies. Transplant Proc 1990; 22: 52-56.
8. Sgoutas D, Macmahon W, Love A, Jerkunica I. Interaction of cyclosporine A with human lipoproteins. J Pharm Pharmacol 1986; 38: 583-588.
9. Warty V, Venkataramanan R, Zendehrouh P et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. Transplant Proc 1991; 23: 954-955.
10. Hughes TA, Gaber AO, Montgomery CE. Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. Ther Drug Monitor 1991;13: 289-295.
11. de Groen PC. Cyclosporine, low density lipoprotein, and cholesterol. Hypothesis. Mayo Clin Proc 1988; 63: 1012-1021.
12. Verrill HL, Girgis RE, Easterling RE, Malhi BS, Mueller WF. Distribution of cyclosporine in blood of a renal-transplant recipient with Type V hyperlipoproteinemia. Clin Chem 1987; 33: 423-428.
13. de Groen PC, Wiesner RH, Krom RAF. Cyclosporine A-induced side effects related to a low total serum cholesterol level: An indication to a free cyclosporine A assay? Transplant Proc 1988; 20(Suppl 2): 374-376.
14. Chung BH, Wilkinson T, Geer JC, Segrest J. Preperative and quantitative isolation of plasma lipoproteins: Rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor. J Lipid Res 1980; 21: 284-291.
15. Allain C, Poon LS, Chan CSG et al. Enzymatic determination of total serum cholesterol. Clin Chem 1974; 19: 470-475.
16. Stinshoff K, Weisshaar D, Stachler et al. Relation between concentration of free glycerol and triglycerides in human sera. Clin Chem 1977; 23: 1029-1032.
17. Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem 1986; 32: 957-961.
18. Moody TW, Kris RM, Fiskum G et al. Characterization of receptors for bombesin/gastrin-releasing peptide in human and murine cells. Methods Enzym 1989; 168: 481-493.
19. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
20. Rodl S, Khoshsorur G. Binding of cyclosporine A to human serum lipoproteins. Transplant Proc 1990; 22: 287-288.
21. Marz W, Zink RA, Graf A et al. Distribution and transfer of cyclosporine among the various human lipoprotein classes. Transplant Proc 1983; 15(Suppl 1): 2426-2429.
22. Marz W, Reble B, Kemkes BM, Knedel M. The role of lipoproteins in exchange and transfer of cyclosporine-results from in vitro investigations. Transplant Proc 1986; 18: 1281-1284.
23. Dieperink H. Temperature dependency of cyclosporin plasma levels. Lancet 1983; i: 416.
24. Humbert H, Vernillet L, Cabiac MD, Barradas J, Billaud E. Influence of different parameters for the monitoring of cyclosporine. Transplant Proc 1990; 22: 1210-1215.
25. Sanghvi A, Warty VS, Diven WF, Starzl T. Receptor-mediated cellular uptake of cyclosporine. Transplant Proc 1989; 21: 858-859.
26. Melzner I, Hambitzer R, Kirkpatrick CJ. Cholesterol synthesis in cultured human peripheral lymphocytes. Influence of LDL, HDL cholesterol/phosphatidylcholine liposomes and complete serum. Biochim Biophys Acta 1986; 875: 439-449.
27. Stone JA, Bowers LD. Low density lipoprotein (LDL)-receptor mediated uptake of cyclosporine in normal and LDL-receptor deficient human fibroblasts. [Abstract] Clin Chem 1992; 38: 1003.
28. Rudling MJ, Reihner E, Einarsson K, Ewerth S, Angelin B. Low density lipoprotein receptor-binding activity in human tissues: Quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo. Proc Natl Acad Sci USA 1990; 87: 3469-3473.